~~Confidential~~

Helsinki, 23 November 2021

Addressees
Registrants of JS-212-990-3 listed in the last Appendix of this decision

Date of submission of the dossier subject of a decision
24/07/2020

Registered substance subject to this decision, hereafter 'the Substance'
Substance name: 2,5-bis(1,1,3,3-tetramethylbutyl)hydroquinone
EC number: 212-990-3
CAS number: 903-19-5

Decision number: Please refer to the REACH-IT message which delivered this communication (in format TPE-D-XXXXXXXXXX-XX-XX/F)

DECISION ON TESTING PROPOSAL(S)

Based on Article 40 of Regulation (EC) No 1907/2006 (REACH), you must submit the information listed below by ***30 November 2022***.

The requested information must be generated using the Substance unless otherwise specified.

A. Information required from the Registrants subject to Annex VII of REACH

1. Long-term toxicity testing on aquatic invertebrates (triggered by Annex VII, Section 9.1.1., column 2; test method: EU C.20./OECD TG 211)

B. Information required from the Registrants subject to Annex VIII of REACH

1. *In vivo* mammalian alkaline comet assay (Annex VIII, Section 8.4., column 2; test method: OECD TG 489) in rats, oral route, on the following tissues: liver, glandular stomach and duodenum.
2. Long-term toxicity testing on fish (triggered by Annex VIII, Section 9.1.3., column 2; test method: EU C.47./OECD TG 210)

Reasons for the request(s) are explained in the appendices entitled "Reasons to request information required under Annexes VII to VIII of REACH", respectively.

Information required depends on your tonnage band

You must provide the information listed above for all REACH Annexes applicable to you, and in accordance with Articles 10(a) and 12(1) of REACH:

- the information specified in Annex VII to REACH, for registration at 1-10 tonnes per year (tpa), or as a transported isolated intermediate in quantity above 1000 tpa;
- the information specified in Annexes VII and VIII to REACH, for registration at 10-100 tpa.

You are only required to share the costs of information that you must submit to fulfil your information requirements.

How to comply with your information requirements

To comply with your information requirements you must submit the information requested by this decision in an updated registration dossier by the deadline indicated above. You must also update the chemical safety report, where relevant, including any changes to classification and labelling, based on the newly generated information.

You must follow the general testing and reporting requirements provided under the Appendix entitled "Requirements to fulfil when conducting and reporting new tests for REACH purposes". For references used in this decision, please consult the Appendix entitled "List of references".

Appeal

This decision can be appealed to the Board of Appeal of ECHA within three months of its notification. An appeal, together with the grounds thereof, has to be submitted to ECHA in writing. An appeal has suspensive effect and is subject to a fee. Further details are described under: http://echa.europa.eu/regulations/appeals.

Approved[1] under the authority of Christel Schilliger-Musset, Director of Hazard Assessment

[1] As this is an electronic document, it is not physically signed. This communication has been approved according to ECHA's internal decision-approval process.

Appendix A: Reasons to request information required under Annex VII of REACH

This decision is based on the examination of the testing proposals you submitted.

1. Long-term toxicity testing on aquatic invertebrates (triggered by Annex VII, Section 9.1.1., column 2)

Short-term toxicity testing on aquatic invertebrates is an information requirement under Annex VII to REACH (Section 9.1.1.). Long-term toxicity testing on aquatic invertebrates must be considered (Section 9.1.1., Column 2) if the substance is poorly water soluble.

Poorly water soluble substances require longer time to reach steady-state conditions. As a result, the short-term tests do not give a true measure of toxicity for this type of substances and the long-term test is required. A substance is regarded as poorly water soluble if, for instance, it has a water solubility below 1 mg/L or below the detection limit of the analytical method of the test material (ECHA Guidance R.7.8.5).

Under Section 4.8 of your technical dossier, you have provided the result of a preliminary examination relating to the water solubility of the substance in the context of an OECD TG 305 study. Additionally, you have provided three supporting studies: QSAR estimations based on the WSKOWWIN model (v1.42), the WATERNT model (v1.02), and the US EPA T.E.S.T. model (4.2). The saturation concentration of the Substance in water was determined to be 0.027 mg/L.

Based on this information ECHA considers the Substance poorly water soluble. Therefore, information on long-term toxicity on aquatic invertebrates must be provided.

1.1. Information provided to fulfil the information requirement

You have submitted a testing proposal for a *Daphnia magna* reproduction test (test method: EU C.20/OECD TG 211).

Your registration dossier does not include any information on long-term toxicity on aquatic invertebrates.

1.2. Test selection and study specifications

The proposed *Daphnia magna* reproduction test (test method: EU C.20/OECD TG 211) is appropriate to cover the information requirement for long-term toxicity on aquatic invertebrates (ECHA Guidance R.7.8.4.1.).

The Substance is difficult to test due to the low water solubility (0.027 mg/L) and due to its other properties: its adsorptive (Log Koc: 5.85), hydrophobic (Log Kow: 5.814), and oxidisable nature (as tetra methyl butyl hydroquinone oxidises to tetramethyl butyl quinone in water). OECD TG 211 specifies that, for difficult to test substances, you must consider the approach described in OECD GD 23 or other approaches, if more appropriate for your substance. In all cases, the approach selected must be justified and documented. Due to the properties of Substance, it may be difficult to achieve and maintain the desired exposure concentrations. Therefore, you must monitor the test concentration(s) of the Substance throughout the exposure duration and report the results. If it is not possible to demonstrate the stability of exposure concentrations (i.e. measured concentration(s) not within 80-120% of the nominal concentration(s)), you must express the effect concentration based on measured values as described in OECD TG 211. In case a dose-response relationship cannot be established (no observed effects), you must demonstrate that the approach used to prepare test solutions was adequate to maximise the concentration of the Substance in the test solutions.

1.3. Outcome

Your testing proposal is accepted under Article 40(3)(a) and you are requested to conduct the test with the Substance, as specified above.

Appendix B: Reasons to request information required under Annex VIII of REACH

This decision is based on the examination of the testing proposals you submitted.

1. In vivo mammalian alkaline comet assay

Under Annex VIII Section 8.4., column 2 of REACH, the performance of an appropriate *in vivo* somatic cell genotoxicity study must be considered if there is a positive result in any of the *in vitro* genotoxicity studies in Annex VII or VIII.

Your dossier contains positive results for the *in vitro* mammalian cell micronucleus test, which raise a concern for chromosomal aberrations.

1.1. Information provided to fulfil the information requirement

You have submitted a testing proposal for an *In vivo* mammalian erythrocyte micronucleus test to be performed with the Substance.

ECHA requested your considerations for alternative methods to fulfil the information requirement for Genetic toxicity *in vivo*. You provided your considerations concluding that there were no alternative methods which could be used to adapt the information requirement(s) for which testing is proposed. ECHA has taken these considerations into account.

1.2. Test selection

ECHA agrees that an appropriate *in vivo* follow up genotoxicity study is necessary to address the concern identified *in vitro.*

According to the ECHA Guidance the *in vivo* mammalian alkaline comet assay ("comet assay", OECD TG 489) or the mammalian erythrocyte micronucleus test ("MN test", OECD TG 474) or the mammalian bone marrow chromosomal aberration test ("CA test", OECD TG 475) are suitable to follow up a positive *in vitro* result on chromosomal aberration if the Substance or its metabolite(s) will reach the target tissue.

However, based on the information provided in the dossier, the genotoxic effect observed in the *in vitro* test(s) is observed only without metabolic activation, which means that the genotoxic effect is due to the parent compound (and not to the metabolites). In the *in vivo* follow up study, the potential effect of the parent (non-metabolised) substance on target tissue(s) can be detected in the comet assay, as site of contact tissues are analysed in this assay. On the contrary, the two other *in vivo* tests, i.e. OECD TG 474 and 475, may not detect the effect of the parent substance as it cannot be ruled out that only the metabolite(s) reach the bone marrow (i.e. the target organ of these tests). Therefore, the *in vivo* comet assay is the most appropriate follow-up test for the Substance.

1.3. Specification of the study design

According to the test method OECD TG 489, the test must be performed in rats.

Having considered the anticipated routes of human exposure and adequate exposure of the target tissue(s) performance of the test by the oral route is appropriate.

In line with the test method OECD TG 489, the test must be performed by analysing tissues from liver as primary site of xenobiotic metabolism, glandular stomach and duodenum as

sites of contact. There are several expected or possible variables between the glandular stomach and the duodenum (different tissue structure and function, different pH conditions, variable physico-chemical properties and fate of the Substance, and probable different local absorption rates of the Substance and its possible breakdown product(s)). In light of these expected or possible variables, it is necessary to analyse both tissues to ensure a sufficient evaluation of the potential for genotoxicity at the site of contact in the gastro-intestinal tract.

Germ cells
You may consider to collect the male gonadal cells from the seminiferous tubules in addition to the other aforementioned tissues in the comet assay, as it would optimise the use of animals. You can prepare the slides for male gonadal cells and store them for up to 2 months, at room temperature, in dry conditions and protected from light. Following the generation and analysis of data on somatic cells in the comet assay, you should consider analysing the slides prepared with gonadal cells. This type of evidence may be relevant for the overall assessment of possible germ cell mutagenicity including classification and labelling according to the CLP Regulation.

1.4. Outcome

Your originally proposed *In vivo* mammalian erythrocyte micronucleus test (EU B.12./OECD TG 474) using the Substance is rejected, according to Article 40(3)(d). Under Article 40(3)(c) you are requested to carry out the additional test with the Substance, as specified above.

2. Long-term toxicity testing on fish (triggered by Annex VIII, Section 9.1.3., column 2)

Under Article 40(3)(c) of REACH, ECHA may require a registrant to carry out one or more additional tests in case of non-compliance of the testing proposal with Annexes IX, X or XI of the REACH Regulation. The information requirement on Aquatic toxicity at Annex IX covers both long-term toxicity on invertebrates (Section 9.1.5.) and on fish (Section 9.1.6.). However, you have provided a testing proposal for long-term testing on aquatic invertebrates only. In case of data gap for long-term toxicity testing on fish, it is necessary to request this information as an additional test to ensure compliance with the endpoint.

Short-term toxicity testing on fish is an information requirement under Annex VIII to REACH (Section 9.1.3.). Long-term toxicity testing on fish must be considered (Section 9.1.3., Column 2) if the substance is poorly water soluble.

Poorly water soluble substances require longer time to reach steady-state conditions. As a result, the short-term tests do not give a true measure of toxicity for this type of substances and the long-term test is required. A substance is regarded as poorly water soluble if, for instance, it has a water solubility below 1 mg/L or below the detection limit of the analytical method of the test material (ECHA Guidance R.7.8.5).

As already explained under Appendix A.1. the Substance is poorly water soluble, and therefore information on long-term toxicity on fish must be provided.

1.1. Information provided to fulfil the information requirement

Your registration dossier does not include any information on long-term toxicity on fish.

Therefore, the information requirement is not fulfilled.

1.2. Test selection and study specifications

The Fish, Early-Life Stage Toxicity Test (test method: OECD TG 210) is appropriate to cover the information requirement for long-term toxicity on fish (ECHA Guidance R.7.8.4.1.).

OECD TG 210 specifies that for difficult to test substances OECD GD 23 must be followed. As already explained under Appendix A.1., the Substance is difficult to test. Therefore, you must fulfil the requirements described in 'Test selection and study specifications' under Appendix A.1.

1.3. Outcome

Under Article 40(3)(c) of REACH, you are requested to carry out the additional test with the Substance, as specified above.

Appendix C: Requirements to fulfil when conducting and reporting new tests for REACH purposes

A. Test methods, GLP requirements and reporting

1. Under Article 13(3) of REACH, all new data generated as a result of this decision must be conducted according to the test methods laid down in a European Commission Regulation or to international test methods recognised by the Commission or ECHA as being appropriate.

2. Under Article 13(4) of REACH, ecotoxicological and toxicological tests and analyses must be carried out according to the GLP principles (Directive 2004/10/EC) or other international standards recognised by the Commission or ECHA.

3. Under Article 10(a)(vi) and (vii) of REACH, all new data generated as a result of this decision must be reported as study summaries, or as robust study summaries, if required under Annex I of REACH. See ECHA Practical Guide on How to report robust study summaries[2].

B. Test material

Before generating new data, you must agree within the joint submission on the chemical composition of the material to be tested (Test material) which must be relevant for all the registrants of the Substance.

1. Selection of the Test material(s)

   The Test material used to generate the new data must be selected taking into account the following:
   - the variation in compositions reported by all members of the joint submission,
   - the boundary composition(s) of the Substance,
   - the impact of each constituent/ impurity on the test results for the endpoint to be assessed. For example, if a constituent/ impurity of the Substance is known to have an impact on (eco)toxicity, the selected Test material must contain that constituent/ impurity.

2. Information on the Test material needed in the updated dossier
   - You must report the composition of the Test material selected for each study, under the "Test material information" section, for each respective endpoint study record in IUCLID.
   - The reported composition must include all constituents of each Test material and their concentration values and other parameters relevant for the property to be tested.

This information is needed to assess whether the Test material is relevant for the Substance and whether it is suitable for use by all members of the joint submission.

Technical instructions on how to report the above is available in the manual on How to prepare registration and PPORD dossiers[3].

[2] https://echa.europa.eu/practical-guides
[3] https://echa.europa.eu/manuals

Appendix D: Procedure

ECHA started the testing proposal evaluation in accordance with Article 40(1) on 2 September 2020.

ECHA held a third party consultation for the testing proposal(s) from 16 December 2020 until 1 February 2021. ECHA did not receive information from third parties.

ECHA followed the procedure detailed in Articles 50 and 51 of REACH.

ECHA notified you of the draft decision and invited you to provide comments.

ECHA did not receive any comments within the commenting period.

ECHA notified the draft decision to the competent authorities of the Member States for proposals for amendment.

As no amendments were proposed, ECHA adopted the decision under Article 51(3) of REACH.

Appendix E: List of references - ECHA Guidance[4] and other supporting documents

Evaluation of available information
Guidance on information requirements and chemical safety assessment, Chapter R.4 (version 1.1., December 2011), referred to as ECHA Guidance R.4 where relevant.

Toxicology
Guidance on information requirements and chemical safety assessment, Chapter R.7a (version 6.0, July 2017), referred to as ECHA Guidance R.7a in this decision.

Guidance on information requirements and chemical safety assessment, Chapter R.7c (version 3.0, June 2017), referred to as ECHA Guidance R.7c in this decision.

Environmental toxicology and fate
Guidance on information requirements and chemical safety assessment, Chapter R.7a (version 6.0, July 2017), referred to as ECHA Guidance R.7a in this decision.

Guidance on information requirements and chemical safety assessment, Chapter R.7b (version 4.0, June 2017), referred to as ECHA Guidance R.7b in this decision.

Guidance on information requirements and chemical safety assessment, Chapter R.7c (version 3.0, June 2017), referred to as ECHA Guidance R.7c in this decision.

Data sharing
Guidance on data-sharing (version 3.1, January 2017), referred to as ECHA Guidance on data sharing in this decision.

OECD Guidance documents[5]
Guidance Document on aqueous–phase aquatic toxicity testing of difficult test chemicals – No 23, referred to as OECD GD 23.

Guidance Document on Standardised Test Guidelines for Evaluating Chemicals for Endocrine Disruption – No 150, referred to as OECD GD 150.

[4] https://echa.europa.eu/guidance-documents/guidance-on-information-requirements-and-chemical-safety-assessment
[5] http://www.oecd.org/chemicalsafety/testing/series-testing-assessment-publications-number.htm

Appendix F: Addressees of this decision and the corresponding information requirements applicable to them

You must provide the information requested in this decision for all REACH Annexes applicable to you.

Registrant Name	Registration number	Highest REACH Annex applicable to you
[redacted]	[redacted]	[redacted]

Where applicable, the name of a third party representative (TPR) may be displayed in the list of recipients whereas ECHA will send the decision to the actual registrant.